Severe ileitis associated with capecitabine: Two case reports and review of the literature
- Authors:
- Published online on: September 2, 2015 https://doi.org/10.3892/mco.2015.635
- Pages: 1398-1400
Metrics: Total
Views: 15840 (Spandidos Publications: 9975 | PMC Statistics: 5865 )
Total PDF Downloads: 4401 (Spandidos Publications: 4080 | PMC Statistics: 321 )
Abstract
Capecitabine is a commonly used anticancer drug, which has been associated with adverse events, including skin and gastrointestinal symptoms, such as vomiting and diarrhea. We herein present treated two rare cases of capecitabine‑associated ileitis. In one of the patients, ileitis occurred during combination chemotherapy for metastatic colon cancer, despite previous good tolerance to this drug; the other patient developed ileitis following adjuvant single‑agent treatment. The first case is unlike previously reported cases, in which patients had no past exposure to capecitabine. Ileitis may be severe but reversible with early diagnosis and proper supportive treatment, and patients may resume chemotherapy following capecitabine discontinuation.
Related Articles
- Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study
- Treatment of capecitabine‑induced hand‑foot syndrome using a topical retinoid: A case report
- A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report
- First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
- Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report